# Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

> **NCT01692483** · — · WITHDRAWN · sponsor: **Janssen Pharmaceutica**

## Conditions studied

- Prostate Neoplasms

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01692483
- **Lead sponsor:** Janssen Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor determined study is not required according to PFDA Circular 2013-004
- **Last updated:** 2015-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692483, "Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01692483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*